1. Cell Cycle/DNA Damage
  2. Nucleoside Antimetabolite/Analog
  3. Sapacitabine

Sapacitabine (Synonyms: CS682; CYC682)

製品番号: HY-16445 純度: 98.51%

Sapacitabine is an orally available nucleoside analog prodrug that is structurally related to cytarabine.


Sapacitabine 構造式

Sapacitabine 構造式

CAS 番号 : 151823-14-2

容量 価格(税別) 在庫状況 数量
10 mM * 1 mL in DMSO USD 132 在庫あり
Estimated Time of Arrival: December 31
5 mg USD 120 在庫あり
Estimated Time of Arrival: December 31
10 mg USD 210 在庫あり
Estimated Time of Arrival: December 31
25 mg USD 440 在庫あり
Estimated Time of Arrival: December 31
50 mg USD 740 在庫あり
Estimated Time of Arrival: December 31
100 mg USD 1240 在庫あり
Estimated Time of Arrival: December 31
200 mg   お問い合わせ  
500 mg   お問い合わせ  

* アイテムを追加する前、数量をご選択ください


Based on 1 publication(s) in Google Scholar

Other Forms of Sapacitabine:

  • CNDAC お問い合わせ
Top Publications Citing Use of Products
  • 生物活性

  • プロトコル

  • 純度とドキュメンテーション

  • 参考文献

  • カスタマーレビュー


Sapacitabine is an orally available nucleoside analog prodrug that is structurally related to cytarabine.

IC50 & Target

nucleoside analog[1]


Concentrations of Sapacitabine required to achieve an IC50 range from 3±0.6 μM for the colon cancer cell line HCT116 to 67±14 μM for the breast cancer cell line MDA-MB-435. Cell cycle analysis shows that 35% Sapacitabine-treated cells are arrested in late-S phase and 41% in G2/M phase. L1210 cells with deoxycytidine kinase (dCK) activity are sensitive to Sapacitabine, (IC50 20±6 μM). In the docetaxel/Sapacitabine combinations, synergistic effects (CI<1) are observed when docetaxel is given before Sapacitabine in both cell lines[1].


On Day 14, the Sapacitabine (5 mg/kg)+vorinostat (33 mg/kg) group has a mean tumour volume of 245 mm3 and a tumour growth inhibition (TGI) of 92%, whereas the Sapacitabine (15 mg/kg)+vorinostat (33 mg/kg) group has a mean tumour volume of 107 mm3 and a TGI of 112%[2].





CAS 番号



O=C(N=C(NC(CCCCCCCCCCCCCCC)=O)C=C1)N1[[email protected]]2[[email protected]@H](C#N)[[email protected]](O)[[email protected]@H](CO)O2


Room temperature in continental US; may vary elsewhere.

Powder -20°C 3 years
  4°C 2 years
In solvent -80°C 6 months
  -20°C 1 month
溶剤 & 溶解度

DMSO : 25 mg/mL (50.95 mM; Need ultrasonic and warming)

Stock Solutions
Concentration Solvent Mass 1 mg 5 mg 10 mg
1 mM 2.0382 mL 10.1908 mL 20.3815 mL
5 mM 0.4076 mL 2.0382 mL 4.0763 mL
10 mM 0.2038 mL 1.0191 mL 2.0382 mL
*Please refer to the solubility information to select the appropriate solvent.

A panel of colon (HT29, HCT116, COLO205, HCC2998), breast (MCF7, MDA-MB-435), lung (HOP62, HOP92), ovarian (OVCAR3, IGROV1) cancer cell lines are used in this study. The cell cycle stage and percentage of apoptotic cells are assessed by flow cytometry. In brief, cells are seeded in 25 cm3 flasks and are untreated or treated with various concentrations of Sapacitabine. At the indicated time points, adherent and non-adherent cells are collected, washed with PBS, fixed in 70% ethanol and stored at 4°C until use. Cells are rehydrated in PBS, incubated for 20 min at room temperature (25°C) with 250 μg/mL RNAse A with Triton X-100 and 20 min at 4°C with 50 μg/mL propidium iodide in the dark. The cell cycle distribution and percentage of apoptotic cells are determined with flow cytometer and analysed by FACS Calibur[1].

MCE はこれらの方法の精度を確認していません。 こちらは参照専用です。


Female (nu/nu) mice are injected subcutaneously with 1×107 MV4-11 cells resuspended in 50% Matrigel at a single site on their flanks. Once tumour volumes are 126 to 256 mm3 (16 days post-implantation) animals are pair matched by tumour size into treatment groups (minimum of six mice per group) with a mean tumour size of ~190 mm3. Tumour measurements are calculated using the formula: volume (mm3)=width2 (mm)×length (mm)×0.5. Sapacitabine is administered once a day orally (5 or 15 mg/kg) for 4 days, followed by a 3-day break before another 4 days of treatment; dosing starts on the same day as distribution to the treatment groups[2].

MCE はこれらの方法の精度を確認していません。 こちらは参照専用です。

  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.
  • モル濃度カルキュレーター

  • 希釈カルキュレーター

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2


SapacitabineCS682CYC682CS 682CS-682CYC 682CYC-682Nucleoside Antimetabolite/AnalogInhibitorinhibitorinhibit



Your information is safe with us. * Required Fields.




お名前 *


PC 用メールアドレス *

電話番号 *


勤務先/学校名 *

Department *


カスタマ需要量 *

国会或いは地域 *





Inquiry Information

MCE 日本正規代理店: